Monthly Newsletter

Effective January 1, 2011, the former Millipore executive, Dominique Baly, has assumed cross-divisional management of marketing, sales and service for the Sartorius laboratory business as President of Sartorius Group Laboratory Business. In this newly created position, he reports to the CEO and is a member of the Group Executive Committee. Sartorius Group highest-level management team is now composed of six individuals, including the Executives of both Sartorius AG and the subgroup Sartorius Stedim Biotech.

For the Sartorius Group, the new management appointment is a key component in the further strategic and operational development of its laboratory business. With the Bioprocess business significant rise in revenue and profit over the past years, the Executive Board is now increasing focus on the laboratory activities of both Group divisions. The major goals of this initiative are the expansion into strategic, fast growing market segments, the targeted extension of the product portfolio and the reinforcement of direct sales organizations in key markets.

"With Dominique Baly, we are gaining an exceptionally experienced and successful manager for our team. He will give our laboratory business decisive momentum in this fast-evolving market environment to define the future positioning for significant growth," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg.

"A strong brand, innovative technologies, a dedicated team and uncompromisingly high quality standards all come together at Sartorius. My goal is to leverage all of the above to build a leading laboratory instruments and consumable business across the world," commented Dominique Baly on his new role at Sartorius.

Dominique Baly is a successful manager in the international laboratory business. He joins Sartorius with more than 35 years of sales and managerial experience for the U.S.-based pharmaceutical supplier Millipore Corporation, which was acquired by Merck KGaA in 2010. From 2005 to 2008, he was President of the $700 millions Bioscience Division. In 2009, he became CEO of Accelerator Sciences LLC, a U.S. investment firm backed by private equity. Baly is of dual nationality, French and American, holds a degree as a pharmacist from the Louis Pasteur University in Strasbourg (France) and has lived and worked in Europe, Asia and the United States of America.